Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis, and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share
Manuel Llobet, CEO at Allergy Therapeutics, stated: “Our convenient, flexible and varied product portfolio has enabled us over the past 19 years to grow revenues at 10% compound annual growth
Thought you left the seasonal sniffles with your sandals and sundresses? Not so fast. Spring isn’t the only season that can make you suffer—autumn is also a red-eyed and runny-nosed
The unforgivable yellow-green dust covers everything it touches. In some well-timed photos, it looks like a smoky film coating hillsides; others show clumps of the sticky stuff coating cars and
A HEATWAVE set to send temperatures soaring this week will leave parts of Britain hotter than southern Spain’s holiday sunspots but hay fever sufferers have been warned pollen levels will
Manuel Llobet, CEO at Allergy Therapeutics plc, said: “This paper validates earlier studies indicating Pollinex Quattro is disease modifying for the many patients affected by grass allergy. Together with the recently
A study shows that Children with autism are twice as likely to be diagnosed with a food allergy as the general population. Youngsters with the condition also have a higher
Allergy Therapeutics plc (LON:AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announced positive new data on its wholly-owned modified house-dust mite subcutaneous immunotherapy1. This data will be
Allergy Therapeutics Plc (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (SCIT), continues to gain market share
Allergy Therapeutics is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (SCIT), continues to gain market share despite being available in
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
